Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Operating Expenses (2016 - 2025)

Regenxbio (RGNX) has 12 years of Operating Expenses data on record, last reported at -$138.3 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 45.22% year-over-year to -$138.3 million; the TTM value through Dec 2025 reached $32.9 million, up 138.11%, while the annual FY2025 figure was $32.9 million, 496.94% up from the prior year.
  • Operating Expenses reached -$138.3 million in Q4 2025 per RGNX's latest filing, down from $9.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $97.6 million in Q3 2022 and bottomed at -$252.4 million in Q4 2024.
  • Average Operating Expenses over 5 years is $49.5 million, with a median of $85.2 million recorded in 2021.
  • Peak YoY movement for Operating Expenses: tumbled 393.06% in 2024, then skyrocketed 4912.06% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $85.1 million in 2021, then grew by 4.77% to $89.1 million in 2022, then fell by 3.37% to $86.1 million in 2023, then plummeted by 393.06% to -$252.4 million in 2024, then soared by 45.22% to -$138.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were -$138.3 million in Q4 2025, $9.6 million in Q3 2025, and $84.6 million in Q2 2025.